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CalmodulinA balance between the proteolytic processing of amyloid precursor protein APP through the amyloidogenic
and the non-amyloidogenic pathways controls the production and release of amyloid β-protein, whose
accumulation in the brain is associated to the onset of Alzheimer Disease. APP is also expressed on circulating
platelets. The regulation of APP processing in these cells is poorly understood. In this work we show that
platelets store considerable amounts of APP fragments, including sAPPα, that can be released upon
stimulation of platelets. Moreover, platelet stimulation also promotes the proteolysis of intact APP expressed
on the cell surface. This process is supported by an ADAMmetalloproteinase, and causes the release of sAPPα.
Processing of intact platelet APP is promoted also by treatment with calmodulin antagonist W7. W7-induced
APP proteolysis occurs through the non-amyloidogenic pathway, is mediated by a metalloproteinase, and
causes the release of sAPPα. Co-immunoprecipitation and pull-down experiments revealed a physical
association between calmodulin and APP. These results document a novel role of calmodulin in the regulation
of non-amyloidogenic processing of APP.Aβ, amyloid β peptide; AD,
+39 0382 987240.
).
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The single transmembrane type I glycoprotein amyloid precursor
protein (APP) is the precursor of the amyloidβ peptide (Aβ), implicated
in the onset of Alzheimer disease (AD) [1]. APP metabolism on the cell
surface is complex, and involves the enzymatic activities of three
differentproteases, actingon twomutually exclusive pathways, referred
to the amyloidogenic and the non-amyloidogenic pathways [2,3]. In the
amyloidogenic pathway, APP is cleaved by β-secretase activity in the
extracellular domain generating a soluble protein named sAPPβ
and unmasking the N-terminal of Aβ sequence which remain anchored
to C-terminal-containing transmembrane fragment. This latter one is
subsequently cleaved byγ-secretase, causing the extracellular release of
Aβ, the 40–42 amino acid peptide which accumulates in amyloid
plaques and manifests neurotoxic activity [4]. In neurons, abnormal
metabolism of APP through the amyloidogenic β-secretase pathway
results in the accumulation of Aβ 1–40 and Aβ 1–42 peptides in the
central nervous system and this is considered to be associated to the
onset of AD, the most common form of dementia in the Western
countries [1]. In the non-amyloidogenic pathway, the extracellular
domain of APP is cleaved by α-secretase which acts within the Aβ
sequence to produce and release a soluble protein called sAPPα, which
incorporates thewhole sAPPβ sequence but also theﬁrst 16 amino acidsof Aβ. Therefore, subsequent action of γ-secretase on the remaining
short transmembrane domain fails to further release neurotoxic Aβ.
Although many studies have highlighted the neurotoxicity of Aβ as a
possible cause for AD, more recent works have proposed that sAPPα
generated by α-secretase may have neuroprotective effects [5,6].
APP is also expressed on circulating cells, and APP proteolytic
fragments are also generated in the plasma [7]. It has been proposed
that the majority of APP found in plasma derives from circulating
platelets [8]. Platelets express APP751 and APP770 isoforms which, in
contrast to the APP695 isoform found in the brain, contain an extra
Kunitz proteinase inhibitor domain at the extracellular N-terminus. In
addition, platelets express α-, β-, and γ-secretase activities, that can
process APP by the same amyloidogenic and non-amyloidogenic
pathways described in the brain, producing the proteolytic fragments
sAPPα, sAPPβ, and Aβ peptide [9]. The role of APP in platelet is
currently unclear. It has been proposed that soluble APP fragments
may regulate thrombosis and haemostasis in vivo through the Kunitz
proteinase inhibitor domain [10], and that a pool of APP soluble
fragments is stored in platelet α-granules and is released upon
platelet stimulation with several agonists [8].
The proteolytic processing of APP on the platelet surface shares some
common feature with the well-described shedding of extracellular
domains of some platelet receptors, including the collagen receptor
GPVI, the GPIbα andGPV subunits of the vonWillebrand factor receptor
GPIb-IX-V complex, and the inhibitory receptor PECAM-1 [11]. Shedding
of these receptors, that represents a mechanism down-regulating
platelet reactivity to extracellular agonists, is promoted by the
membrane localized metalloproteinases ADAM10 and ADAM17, and is
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demonstrated that binding of calmodulin to the cytoplasmic tail of GPVI
andGPIb-IX-V prevents shedding of the receptors, and disruption of this
interaction by calmodulin antagonists or by mutagenesis of the
calmodulin-binding sequence in the receptors results in the activation
of ADAM and ectodomain shedding [14,15]. Since ADAM10 and
ADAM17 have been demonstrated to display α-secretase activity
responsible for the release of sAPPα fromAPP [16], we have investigated
the possible role of calmodulin in the regulation of the non-amyloido-
genic processing of APP on the platelet surface.2. Materials and methods
2.1. Materials
Antibodies (Abs) against APP 5352 and 22C11 were from Chemicon
(Milan, Italy), and 6E10 from Covance (Princeton, NJ, USA). Anti-
calmodulin antibodywas fromUpstate Biotechnology (Lake Placid, NY).
Anti-GPIbα antibody SZ2 was from Immunotech (Marseille, France).
Thrombin, ADP, puriﬁed calmodulin, and PA–Sepharose were from
Sigma (Milan, Italy). Convulxin was provided by Dr. K. J. Clemetson
(Theodor Kocher Institute, University of Berne, Switzerland). HEK293
cells stably expressing APP751 were kindly provided by Prof. M. Racchi
(Department of Experimental and Applied Pharmacology, University of
Pavia, Italy). Type I collagenwasprovidedbyProf. E. Tira (Departmentof
Biochemistry, University of Pavia). Calmodulin–Sepharose 2B and
Sepharose 2B were from GE Healthcare (Cologno Monzese, Italy).
GM6001 was from Calbiochem. U46619 and W7 were from Alexis
(Milan, Italy). The expression plasmid pGeX-4T3 and the glutathione–
Sepharosewere fromGEHealthcare.DulbeccomodiﬁedEagle'smedium
(DMEM), glutamine, penicillin, streptomycin and G418 were from
Euroclone. Chemiluminescent substrate was from Pierce (Milan, Italy).2.2. Platelet preparation and stimulation
Washed human platelets were isolated from healthy donors and
resuspended in Hepes buffer as previously described [17]. Platelet
samples (0.1 ml, 109 platelets/ml) were incubated at 37 °C, and
stimulatedwith1U/ml thrombin, 10 μMU46619, 10 μg/ml collagen, 100
ng/ml convulxin, and 10 μM ADP for 15 min. Treatment with the
calmodulin antagonist was typically performed by addition of 200 μM
W7 for 2 h, unless differently stated in the ﬁgure legend. Platelet pellet
was separated from platelet releasate by centrifugation at 2700g for 5
min. Platelet pellet was solubilized with 120 μl of 2% SDS, and platelet
releasate was dissociated by addition of 20 μl of SDS 12%. Samples were
then prepared for subsequent SDS-PAGE analysis by addition of 60 μl of
sample buffer 3X (37.5 mM Tris, 288mM glycine, pH 8.3, 1.5% DTT, 30%
glycerol, 0.03%bromophenol blue). In someexperiments, proteins in the
releasate were precipitated by addition of a volume of 20% TCA for 1 h.
Precipitates were washed three times with water, and then solubilized
in 1/10 of the original volume, before addition of 2% SDS.2.3. Cell culture
HEK293 cells stably expressing APP751 were maintained in DMEM
supplemented with 10% fetal calf serum, 2 mM glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin sulfate in a humidiﬁed 5% CO2
atmosphere at 37 C in the presence of 500 μg/ml G418 antibiotic. For the
proteolysis and pull-down experiments, 1×106 cells were grown in
complete medium for 24 h and then incubated with 200 μMW7 and/or
100 μM GM6001 in fresh medium. Two hours later, medium was
discharged, and cells were resuspended in PBS, recovered by centrifu-
gation, and lysed in 100 μl ice cold lysis buffer (Tris 50 mM, NaCl 200
mM, Nonidet P-40 1%, Na deoxycholate 0.5%, SDS 0.1%, pH 7.4).2.4. Immunoprecipitation and pull-down assay
For immunoprecipitation studies, platelets or platelet releasates
were lysed in ice cold lysis buffer, and centrifuged at 17,000g for 10min
to remove insolublematerial. For co-immunoprecipitation experiments,
platelet lysis was performed under milder condition using a different
lysis buffer (Tris 50 mM, NaCl 200 mM, Nonidet P-40 1%, Na
deoxycholate 0.5%, pH 7.4). APP was immunoprecipitated with 1 μg
5352 mAb for 2 h at 4 °C and the immunocomplexes were precipitated
by addition of 90 μl protein A Sepharose for 45 min at 4 °C. After brief
centrifugation, immunocomplexes were washed three times with 1 ml
of lysis buffer, and ﬁnally resuspended in 25 μl of SDS sample buffer 2X.
For pull-downassayswashed platelets orHEK293-APP751 cellswere
lysed with HEPES 20 mM, KCl 200 mM, Triton X-100 0.55%, pH 7.4.
Lysates were precleared with 90 μl Sepharose 2B under gentle rocking,
and incubatedwith 90 μl calmodulin–Sepharose 2B in calmodulin buffer
(HEPES 20 mM, KCl 200 mM, pH 7.4) for 2 h. After extensive washing,
immobilizedproteinswere resuspended in25 μl of SDS samplebuffer2X.
2.5. Electrophoresis and immunoblotting
Proteinswere separated on 7.5% and 16% linear or 10–20% gradient
acrylamide gels, and transferred to nitrocellulose. Membranes were
blocked 2 h at room temperature with 6% BSA in Tris buffer saline (20
mM Tris–HCl, pH 7.5, 0.5 M NaCl) and incubated with the anti-APP
Abs 5352, 22C11 and 6E10 (1:1000 dilution), or with anti-calmodulin
or anti-GPIbα antibodies (1:1000 dilution). Membranes were exten-
sively washed with 50 mM Tris–HCl, pH 7.4, 0.2 M NaCl, 1 mg/ml
polyethylene glycol 20000, 1% BSA, 0.05% Tween 20, and incubated
with peroxidase-conjugated secondary antibody (1:3000 dilution) for
45 min. Immunoreactive proteins were detected by chemilumines-
cent reaction and visualized by Chemidoc XRS (Biorad).
2.6. Production of GST fusion proteins and binary assay
ToproduceGST fusion proteins, a PCR reactionwas initially conducted
to amplify the sequenceof cDNAcoding thehuman isoformAPP751using
the following primers: 5′-CGC GGA TCC AAG AAA CAG TAC ACA TCC-3′
and 5′-CCG GAA TTC TCA TTA GTT CTG CAT CTG CTC AAA GAA-3′, for the
fusion proteinGST(691–705)APP; 5′-CCGGAATTC TCATTAGTTCTGCAT
CTG CTC AAA GAA-3′ and 5′GGC GGA TCC TGT TGT CAT AGC GAC AGT
GAT-3′, for the fusion protein GST(705–751)APP. The cDNAswere cloned
into theexpressionplasmidpGeX-4T3 into theBamHIandEcoRI sites. The
constructs obtained were used to transform the E. coli BL21. After
sonication in the presence of 1% TritonX-100, the cytosol of bacteria
expressing the GST fusion proteins was incubated with glutathione–
Sepharose for 2 h at 4 °C followed by 3 sequential washes in phosphate
buffer saline. Fusion proteinswere eluted in elute buffer (20mMTris, 100
mM NaCl, 10 mM GSH, 5 mMMgCl2, 1% Glicerolo, 5 mM DTT, pH 8.00),
dialyzed into PBS, and cleared by centrifugation, and aliquots of these
fractions were analyzed by SDS-PAGE.
Twenty micrograms of fusion proteins GST(691–705)APP or GST
(705–751)APP were incubated with 20 μg of puriﬁed calmodulin and
glutathione–Sepharose in binding buffer (20mMHEPES, 100mMKCl,
pH 7.4) for 2 h at 4 °C. After three washing in binding buffer, the beads
were eluted with SDS sample buffer and analyzed by SDS-PAGE.
3. Results
The analysis of APP expression and metabolism in resting and
stimulated human platelets was performed using three different
antibodies (Abs) directed towards different regions of the protein
(Fig. 1A). The 22C11 mAb binds to the N-terminus of APP, and, thus, is
able to detect full-length APP, as well as the soluble fragments sAPPα
and sAPPβ; the 6E10 mAb is directed to the ﬁrst 16 amino acids of Aβ
peptide, and thus it also recognizes sAPPα produced upon APP
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intracellular C-terminus of APP, and therefore can be used to detect APP,
but not sAPPα or sAPPβ.Washed human platelets were lysed with SDS sample buffer and
aliquots corresponding to the same number of cells were separated by
SDS-PAGE on 7.5% acrylamide gradient gel, transferred to nitrocellulose
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antibody recognized a single band of about 140 kDa corresponding to
the molecular mass expected for the full-length membrane-associated
APP. However, the 22C11 mAb detected a major prominent band of
about 120 kDa, which is smaller than that expected for full-length APP,
and may represent a proteolytic fragment of APP preserving the N-
terminus. This is supported by theﬁnding that the 120 kDa banddid not
include the intracellular C-terminal domain of APP, as it was not
detected by the 5352 Ab. Moreover, the reactivity with the 6E10 mAb
indicates that this band included the soluble fragment sAPPα. The
available antibodies do not allow to ascertain whether sAPPβ is present
in this band, as well. The differences in reactivity to the 22C11 mAb of
the 140 and 120 kDa band suggest that either the full-length APP is
much less abundant than its smaller fragment, or that the 140 kDa band
recognized by the 5352mAbdoes not contain theN-terminus of APP. To
deﬁnitively demonstrate that the protein in the 140 kDa band also
contained the APP N-terminus, we adopted a different strategy. The 140
kDa protein was immunoprecipitated with the 5352 Ab, and the
enriched preparation was immunoblotted with both the 5352 and
22C11 mAbs. Fig. 1C shows that the immunoprecipitated 140 kDa band
wasdetected also by the 22C11mAb. These results demonstrate that the
140 kDa band is the authentic full-length APP, which, however, is much
less abundant in platelets than the sAPPα fragment. We therefore
identiﬁed the 120 kDa band recognized by 22C11 and 6E10 as sAPPα,
and the 140 kDa recognized by the 5352 Ab as APP.
We next examined the changes in the distribution of these proteins
induced by platelet stimulation.Washed platelets were left untreated or
were stimulated with different platelet agonists, including thrombin
(1U/ml), ADP (10 μM), the thromboxane A2 analogue U46619 (10 μM),
collagen (10 μg/ml), or with the GPVI agonist convulxin (100 ng/ml) for
15minunder constant stirring, and aplatelet pelletwas separated froma
platelet releasate (supernatant) by centrifugation at 2700g for 5 min.
Both fractionswere solubilizedwith 2% SDS anddissociatedwith sample
buffer and aliquots corresponding to the same number of cells were
analyzed by immunoblottingwith the three anti-APP Abs. Upon platelet
stimulation with thrombin, U46619, and collagen or convulxin, but not
ADP, the 120 kDa band detected by the 22C11 and 6E10 mAbs was no
longer present in the platelet pellet, but appeared in the releasate. This
indicates that platelet stimulation with strong agonists induced the
release of a pool of sAPPα stored in the platelet, and is consistent with
previousﬁndings localizing sAPPα in plateletα-granules [7,8]. The same
agonists also caused the disappearance of the 140 kDa full-length APP
identiﬁed by the 5352 Ab. As expected, this antibody did not recognize
any protein of comparable molecular mass in the releasate. These
observations suggest that platelet stimulation with strong agonists also
causes proteolysis of the full-length APP. It is likely that the direct
detection in the supernatant of the newly generated APP proteolytic
fragments (sAPPα and/or sAPPβ) with the 22C11 or 6E10 antibody is
masked by the concomitant agonist-induced release of a much greater
amount of soluble fragments already present in the platelet. Proteolysis
of full-length APP from the platelet surface also occurred in plasma.
Fig. 1E shows that when platelet rich plasma (PRP) was treated with a
mixtureof thrombin receptors activatingpeptides (mimicking theaction
of thrombin), or with U46619, full-length APP was no longer detectable
in the platelet pellet. By contrast, ADP, which was unable to trigger APPFig. 1. Analysis of APP expression andmetabolism in resting and stimulated platelets. A. The sch
in this study (22C11, 6E10, and 5352). The transmembrane region of APP is indicated by the para
action of the β- and γ-secretases, that act at the points indicated by the arrows. α-Secretas
Immunoblotting ofwhole platelet lysatewith the threeAbs, as indicated on the top of eachpane
were lysed, and full-length APP was immunoprecipitated with the 5352 Ab. A non-related antib
aliquot of whole cell lysate (total), were separated on a 7.5% acrylamide gel and probed by imm
(none) or stimulatedwith the agonists indicated on the bottomof thepanel. Platelet pellets and
fragments was investigated by immunoblotting analysis performed on corresponding aliquots
PRPwerestimulatedwith10μMPAR1activatingpeptide and0.5mMPAR4activatingpeptide, 10
the platelet pellet was investigated by immunoblotting with the anti-5352 antibody. F. Aliquot
and 16% acrylamide gel, and analyzed by immunoblotting with the 5352 Ab against the intr
intracellular domain of APP, GST(705–751)APP was also loaded as positive control for the immproteolysis in washed platelets, also failed to cause the disappearance of
the 140 kDa band from the platelet pellet in PRP (Fig. 1E). In an attempt
to analyze thepresence of APP C-terminal fragments, as a furthermarker
of agonist-induced APP proteolysis, we utilized a SDS–tricine gel which
resolves proteins with very low molecular weight. However we have
been unable to highlight any protein of low molecular mass recognized
by the 5352 antibody in platelets stimulated with thrombin, under
conditions inwhichconcomitantdisappearanceof the140kDabandwas
evident (Fig. 1F). Similar results were also obtained with all the other
platelet agonists (data not shown). This observation could be explained
in the light of the previously documented instability of these fragments
and of their possible degradation, mediated by secretases and caspases
[18,19]. Altogether, these sets of experiments demonstrate that the
hydrolysis of APP in intact platelet is induced by several agonists, but can
only be evaluated by measuring the disappearance of the 140 kDa band
reactive to the 5352 Ab.
Agonist-induced proteolysis of APP in intact platelet was not
dependent on platelet aggregation, as it was also observed in the absence
of stirring or in the presence of integrin αIIbβ3 antagonists (data not
shown). Moreover, as indicated by the representative experiments with
thrombin-stimulated platelets reported in Fig. 2A, agonist-induced
proteolysis of platelet APP was prevented by EDTA or by preincubation
with GM6001, a broad range inhibitor of protease of the ADAM family.
Different platelet-speciﬁc receptors, including GPIbα, GPV and GPVI, are
shed by ADAM metalloproteinases during platelet activation, and this
process was reported to be mediated by dissociation of calmodulin
[12,13]. We therefore askedwhether also the proteolysis of APP could be
regulated by calmodulin. Platelets were preincubated with the calmod-
ulin antagonistW7 or with thrombin, and APP proteolysis was evaluated
as disappearance of the 140 kDa band, upon immunoblotting analysis of
the platelet pellet with the 5352 Ab. Fig. 2B shows that, as seen for
thrombin stimulation,W7 treatment caused the disappearance of the 140
kDa APP in platelets. Identical results were also obtained when platelets
were incubated with a structurally different calmodulin inhibitor
Ophiobolin A (data not shown). Therefore calmodulin antagonists cause
the proteolysis of APP in intact platelets. We also analyzed the possible
effect of W7 on the redistribution of the more abundant 120 kDa sAPPα
fragmentofAPP, lacking theC-terminus. Interestingly, in contrast to other
agonist like thrombin,W7 treatment of platelets did not cause the release
of this fragment from the platelet to the supernatant. This indicates that
calmodulin antagonists promote the hydrolysis of APP on the platelet
surface, but not the release of previously generated APP fragments stored
in platelets. In agreement with this conclusion, we found that, in contrast
to thrombin,W7 did not cause platelet aggregation and did not stimulate
exposure of P-selectin, a speciﬁcmarker of plateletα-granules, indicating
that it did not trigger platelet activation and secretion (data not shown).
Fig. 2C shows that APP hydrolysis induced by the calmodulin antagonist
W7 was time- and dose-dependent: it was already evident within
minutes and completed in 2 h.
W7-induced proteolysis of APP was mediated by a metalloprotein-
ase, as it was prevented by incubation with EDTA or by the broad range
ADAM inhibitor GM6001 (Fig. 3A). In this context, APP proteolysis in
platelets occurred through a mechanism comparable to that previously
described for other platelet glycoproteins [12]. This is also conﬁrmed by
the ﬁnding that similarly to APP, also platelet GPIbα was proteolyzedeme presents the location on theAPPmolecule of the epitopes bound by the three Abs used
llel solid lines. The gray box localizes theAβ peptidewhose release requires the sequential
e proteolyses APP within the Aβ sequence, and unmasks the epitope for 6E10 mAb. B.
l. The positions of themolecularmassmarkers are indicated on the left. C.Washedplatelets
ody (NRS) was used in control immunoprecipitation. Precipitated proteins, along with an
unoblottingwith the 22C11 (left) and the 5352 (right) Abs. D. Platelets were left untreated
supernatants (releasate)were separated by centrifugation. Thedistribution of APP andAPP
of each fractionwith the 22C11, 5352, and 6E10 Abs, as indicated on the top. E. Platelets in
μMADP, 10μMU46619, orwere left untreated(none), as indicated.ThepresenceofAPP in
s of resting (none) and thrombin-stimulated platelets (thrombin) were separated on 7.5%
acellular domain of APP. In a parallel lane, an aliquot of a fusion protein expressing the
unoblot from the 16% acrylamide gel.
Fig. 2. APP proteolysis is regulated by calmodulin. A. Platelets were incubated in the absence (none) or presence of themetalloproteinase inhibitor GM6001 (100 μM, 15min) or with
EDTA (10mM, 10min) as indicated, and then left untreated or stimulatedwith 1 U/ml thrombin for 15min. Platelet lysates were then analyzed by immunoblotting with the 5352 Ab.
B. Resting platelets (none), platelets treated with 200 μMW7 for 2 h (W7), and platelets stimulatedwith 1 U/ml thrombin for 15min (thr) were collected by centrifugation, lysed and
analyzed by immunoblotting with the different anti-APP Abs indicated on the top. In parallel, the same analysis was performed on corresponding aliquots of the supernatant
(releasate). C. Time-course and dose-dependent proteolysis of platelet APP induced by calmodulin antagonist W7. APP proteolysis was quantiﬁed by densitometric analysis of
immunoblots with the 5352 Ab, and data are expressed as percentage of disappearance of the 140 kDa band. Results are the means±SD of three different experiments.
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andGM6001 (Fig. 3A). To verifywhether the observed sensitivity toW7
was a peculiar feature of APP expressed on the platelet surface, we
analyzed HEK293 stably expressing APP751. Fig. 3B shows that W7
caused proteolysis of APP also in transfected HEK293 cells, and this
process was inhibited by GM6001. Proteolysis of APP on the plasma
membrane is typically promoted by α-secretase, and the GM6001-
sensitive ADAM17, which is expressed in platelets, displaysα-secretase
activity [16]. Moreover, ADAM17mediatesW7-induced shedding of the
extracellular domain of some platelet glycoproteins, including GPIbα
[14,15]. We therefore hypothesized that W7 stimulated the non-
amyloidogenic processing of APP, releasing APPα. Because of the low
amount of APP expressed on platelets, we were unable to detect any
released fragments by direct immunoblotting analysis of the superna-
tant (Fig. 2A).We therefore precipitated the proteins released fromW7-
treated platelets with TCA and performed an immunoblotting analysis
on these enriched fractions. Fig. 3C shows that platelet treatment with
W7 caused the accumulation in the supernatant of an APP fragment
recognized by the 6E10mAb, and thus identiﬁed as sAPPα. The different
intensity of the bands recognized by 22C11 and 6E10 mAbs may be
related to the different sensitivity of the two antibodies. Moreover,
release of sAPPα by W7 was prevented by the metalloproteinase
inhibitor GM6001. Taken together these results demonstrated that
calmodulin promotes ADAM-mediated proteolysis of APP through the
non-amyloidogenic pathway, resulting in sAPPα production.
W7 is a competitor of calmodulin binding to target proteins. In
order to characterize the mechanism of W7-induced proteolysis of
APP, we investigated whether calmodulin was able to interact with
APP in intact platelets. APP was immunoprecipitated from resting
platelets with the 5352 Ab in the presence of CaCl2 or EGTA.
Immunoprecipitates were analyzed for the presence of calmodulinby immunoblotting with a speciﬁc antibody. Fig. 4A shows that
calmodulin speciﬁcally coimmunoprecipitated with APP in the
presence of EGTA but not in the presence of CaCl2, suggesting a
physical interaction between the two proteins, that is antagonized by
Ca2+. Moreover, we also found that in pull-down experiments
immobilized calmodulin was able to precipitate APP from a platelet
lysate, as well as from HEK293 cells stably expressing APP751.
Screening of APP sequence using the calmodulin target database
indicates the presence of two potential binding sites for calmodulin
on APP751, encompassing amino acids 694–713 in the intracellular
domain, and amino acids 446–468 in the extracellular portion. In an
attempt to characterize calmodulin binding to APP, we generated
and puriﬁed a GST fusion protein containing the entire cytoplas-
matic domain of APP751 (APP705-751). Moreover, since the
calmodulin-binding sequence in APP751 also includes a signiﬁcant
portion of the APP transmembrane domain, we generated and
puriﬁed also a GST-APP691-705 fusion protein. These constructs
were used for in vitro binding assays with puriﬁed calmodulin.
Unfortunately, we were unable to detect any speciﬁc association of
calmodulin with the GST fusion proteins (Fig. 4C). Altogether, our
results indicate that the modality of their biochemical interaction
may be more complex than expected, but clearly identify calmodulin
as a binding partner of APP.
4. Discussion
In thisworkwehavedemonstrated thatexposure of humanplatelets
to the calmodulin inhibitor W7 causes the non-amyloidogenic prote-
olysis of APP, and the release of sAPPα fragments. In the brain, the
balance between amyloidogenic and non-amyloidogenicmetabolism of
APP has important physiological implications. Proteolysis through the
Fig. 3. W7 stimulates non-amyloidogenic proteolysis of APP. A. Platelets were treated
with buffer (none), or withW7 in the presence of GM6001 or EDTA, as indicated. Whole
platelet lysates were tested by immunoblotting with the 5352 mAb to detect
proteolysis of APP (upper panels) or with the anti-GPIbα mAb SZ2 (lower panel). B.
HEK293 (HEK) cells and HEK293 cells stably expressing APP751 (HEK751APP) were left
untreated (none), or were incubated with 200 μMW7 for 2 h in the absence or presence
of 100 μM GM6001. Cells were recovered, lysed, and analyzed by immunoblotting with
the 5352 Ab to detect full-length APP. C. Proteins in the supernatant of resting platelets
(−) or of platelets treated with W7 (W7) in the presence (+) or absence (−) of
GM6001 were precipitated with TCA, and analyzed for the presence of APP fragments
by immunoblotting with the 22C11 and 6E10 mAbs, as indicated on the top.
Fig. 4. APP binding to calmodulin. A. Resting plateletswere lysed and immunoprecipitated
with the 5352 mAb or with non-related immunoglobulins (NRI) in the presence of 1 mM
CaCl2 or 2 mM EGTA, as indicated on the bottom. Immunoprecipitated proteins were
separated on a 10–20% acrylamide gradient gel, and transferred to nitrocellulose.
Membranes were cut at the level of the 45 kDa marker: the upper part was probed with
the 22C11 mAb to detect immunoprecipitated full-length APP, and the lower part was
probed with an anti-calmodulin antibody. An aliquot of whole platelet lysate (WPL) was
analyzed in parallel. B. Resting platelets and APP751-expressing HEK cells were lysed and
incubated with calmodulin–Sepharose 2B (CaM-Sepharose) or an equivalent amount of
Sepharose 2B. Proteins precipitated by immobilized calmodulin were separated on 7.5%
acrylamide gel, and probed for the presence of APP by immunoblotting with the 22C11
mAb. C. PuriﬁedGST-taggedAPP intracellular fragments GST(691–751)APP andGST(705–
751)APP (20 μg), or GST alone, used as control, were incubated with 20 μg of puriﬁed
calmodulin. Recombinant proteins were precipitated with glutathione–Sepharose and
analyzed by immunoblotting with anti-calmodulin antibody. A small aliquot of puriﬁed
calmodulinwas also loaded on the same gel, as positive control. The reported immunoblot
is representative of three different experiments.
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associated to the accumulation of the neurotoxic Aβ peptide and to
the onset of Alzheimer Disease, while the non-amyloidogenic pathway,
initiated by α-secretase activity, not only prevents the subsequent Aβ
production, but also generates sAPPα, that may exert a neuroprotective
action. APP is also expressed in circulating platelets, and a mounting
body of evidence indicates that platelets may represent an excellent
peripheral model to study APP metabolism [20].
Early studies have proposed that the majority of platelet APP is
stored as proteolyzed fragments into the α-granules, and it is released
upon platelet activation, while only a minor population is expressed as
an intact protein on the cell surface [21,22]. Here we have strengthened
these observations, aswe found that themajority of APP is detectable in
platelets as a fragment lacking the C-terminal domain, and is released in
the supernatant upon activation by those agonists, like thrombin or
U46619, able to induced secretion, but not by those, like ADP, which do
not induce the release of internal granules from washed platelets. The
precise nature of the APP fragments stored in platelets in uncertain. By
using a speciﬁc antibody, we have demonstrated that this fragment
includes sAPPα, the main product of the non-amyloidogenic pathway.
However, the available tools do not allow to ascertain whether or not
sAPPβ is also present. Evidence that platelets can process APP through
the amyloidogenic pathway derives from the reported secretion of Aβ
from stimulated platelets [23]. By using commercially availableimmunological assays, we have tried to measure Aβ both in the pellet
and in the supernatant of resting or thrombin-stimulated platelets.
However, we have been unable to measure detectable amount of this
peptide in either fractions (data not shown). Therefore, our own
observations argue against a major role for platelets in the production
and releaseof amyloidogenicAβpeptide, and suggest that these cells are
mainly involved in sAPPα production.
We found that platelet stimulation not only cause the secretion of
stored sAPPα, but also promotes the proteolysis of intact, membrane-
associatedAPP, thus causing a further release of newly generatedpool of
sAPPα. Moreover, we found that, even in the absence of platelet
stimulation, proteolysis of intact APP in platelets can be triggered
506 I. Canobbio et al. / Biochimica et Biophysica Acta 1813 (2011) 500–506by treatment with calmodulin inhibitors. Importantly, calmodulin
inhibitors did not cause platelet secretion, and did not trigger the
release of stored APP fragments. We also found that calmodulin-
regulated proteolysis of APP is mediated by a metalloproteinase of the
ADAM family. It has been previously reported that several platelet
membrane glycoproteins undergo metalloproteinase-dependent pro-
teolysis upon treatment with calmodulin antagonists or upon platelet
stimulationwith extracellular agonists [24]. These glycoproteins include
several platelet-speciﬁc receptors, such as GPIbα, GPV, and GPVI, and
the shedding of their soluble ectodomains has been generally
interpreted as a mechanism for down-regulating platelet responsive-
ness to extracellular stimulation [25]. Our ﬁndings demonstrate that a
similar mechanism also promotes non-amyloidogenic processing of
APP, which is not a platelet-speciﬁc glycoprotein. Moreover, the ﬁnding
that W7 causes proteolysis of APP also in HEK293 cells expressing
APP751 indicates that sensitivity to calmodulin inhibitors is an intrinsic
feature of APP, and it is not restricted to platelet. In platelets,
calmodulin-regulated shedding of GPIbα, GPV or GPVI has been
documented to be mediated by the membrane-associated metallopro-
teinases ADAM10 and ADAM17 [12]. We have found that an ADAM
metalloproteinase is also responsible for agonist- or W7-induced APP
proteolysis. Importantly, both ADAM10 and ADAM17 have been shown
to possess α-secretase activity, and we found that APP proteolysis
releases sAPPα.
As a calmodulin antagonist, the compound W7 is able to dissociate
calmodulin from its target proteins. All the platelet membrane glycopro-
teins whose proteolysis is promoted by W7 have been demonstrated to
bind calmodulin through their intracellular domain [14,15]. In thismodel,
W7-mediated dissociation of calmodulin from the receptor results in the
activation of an ADAM and in the subsequent proteolysis of the receptors
and ectodomain shedding. In line with this model, we have here
demonstrated by means of co-immunoprecipitation and pull-down
experiments that calmodulin interacts with APP in intact platelets.
Therefore, our study indicates that calmodulin is to be considered as a
novel APP binding partner. The association of calmodulin with APP was
Ca2+-sensitive and was prevented when CaCl2 was added to the cell
lysate. Accordingly, APP processing byα-secretase activity and release of
sAPPαwas also observed upon platelet treatmentwith a Ca2+ ionophore
(data not shown). These ﬁndings suggest that non-amyloidogenic
processing of APP induced by physiological platelet agonists may be
mediated by the increase of the cytosolic Ca2+, causing calmodulin
dissociation, as seen upon treatment with W7.
Our in vitro binding assays with recombinant GST-fused proteins
containing the potential intracellular calmodulin-binding site on
APP751 failed to reveal a direct binding with calmodulin. Although it
is possible that the constructs were not properly folded, these results
suggest that the interaction of full-length APPwith calmodulinmay not
be direct, but involves other still unidentiﬁed partners. A previous work
has reported that calmodulin can associate to ADAM10, and it has
been suggested that the modiﬁcation of this interaction by intracellular
Ca2+ may regulate ADAM10 activation [26]. Since ADAM10 possesses
α-secretase activity, it is possible that non-amyloidogenic proteolysis of
platelet APP by the calmodulin antagonist W7, or by physiological
agonists is a consequence of a perturbation of calmodulin binding to
ADAM10 rather than to APP itself.
In conclusion, our work reports a novel mechanism regulating non-
amyloidogenic processing of APP,which involves calmodulin dissociation
and activation of theα-secretase activity of an ADAM family metallopro-
teinase. Itmay be interesting to consider thatα-secretase cleavage of APP
on the plasma membrane prevents subsequent generation of the
neurotoxic Aβ peptide through the amyloidogenic pathway, which
occurs on intracellular compartments during endocytosis and recycling of
APP. Therefore, calmodulin may represent a novel target to alter the
balance between amyloidogenic and non-amyloidogenic metabolism of
APP in intact cells resulting in an increased release of sAPPα, and reducing
the production and accumulation of Aβ peptide.Acknowledgements
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